Oligopeptide-1: evidence, FDA status and research

An ingredient in skin serums sold to renew skin and soften fine lines. It has only been tested in a few small studies, such as 18 people without a comparison group.

Sold for

Oligopeptide-1 is sold in growth-factor serums promising faster skin renewal, firmer texture and fewer fine lines.

Studies say

EGF has a well-understood role in wound healing, but the cosmetic evidence is a handful of small, short, uncontrolled or industry-run studies, which is C-grade support.

Why grade C. The human evidence in these sources is an open pilot study of an EGF serum in 18 volunteers with no control group. Larger controlled trials of oligopeptide-1 as a cosmetic have not been identified, and those that exist test it inside multi-ingredient products. Uncontrolled series put it at C. ¹

FDA. Oligopeptide-1 is the cosmetic ingredient name for epidermal growth factor. In skincare it is regulated as a cosmetic and is not approved by the FDA as a drug for any use; the FDA does not approve cosmetic ingredients before sale. ²³

Written from 3 cited sources. Fact-checked 2026-10-27: 8 claims checked, 0 corrected. Last refreshed 2026-10-27. Not physician reviewed.

What this means for you

What people take it for: Renewing skin and smoothing fine lines.
Can a US doctor prescribe it?: No prescription; it is a cosmetic ingredient.
Properly tested in people?: Not properly: animal or lab studies, or small uncontrolled human reports. one 18-person study with no comparison group.

Evidence checklist

Randomised controlled trial Open pilot only, no control groupno
Human study over 100 people Pilot had 18 volunteersno
More than one research group Other studies use multi-ingredient productsno
Clinical outcomes, not surrogate markers Investigator-graded under-eye bagsno
Human safety data beyond case reports Small, short studies; long-term unknownno

Drawn from the cited studies below. A dash means the sources give no information.

What it is

Oligopeptide-1 is the INCI label name for epidermal growth factor (EGF), a 53-amino-acid protein that the body uses to signal skin cells to divide and migrate. Cosmetic versions are made by recombinant methods in bacteria, yeast or plants, which is why labels sometimes read sh-oligopeptide-1 (synthetic human) or rh-oligopeptide-1 (recombinant human). ¹³

The discovery of EGF won a Nobel Prize in 1986 and recombinant EGF has been used medically for burns and diabetic ulcers in several countries. Cosmetic use borrows that reputation. In the United States, a product containing it is a cosmetic unless it claims to treat a condition, in which case it would be an unapproved drug. ²³

How it works

EGF binds the EGF receptor on keratinocytes and fibroblasts and triggers signaling that increases cell division, migration and the production of matrix proteins such as collagen. In a wound this speeds closure. The cosmetic claim is that the same signal, applied to intact aging skin, thickens the epidermis and improves texture. The open question is penetration: EGF is a large, water-soluble protein and intact skin is designed to keep such molecules out. ¹

What human research shows

The identifiable human study is a 2015 open pilot in which 18 volunteers applied an EGF serum twice daily to the under-eye area; 16 completed it. Investigator grading showed a significant reduction in under-eye bag severity and most participants reported improvement. There was no placebo or vehicle control, so the contribution of EGF versus the base formulation and the act of regular application cannot be separated. ¹

Other published work on EGF in skincare tests it in combination with lasers, hyaluronic acid or antioxidant blends, which says something about the product but little about the peptide on its own. A controlled trial of oligopeptide-1 alone in aging skin has not been identified in these sources. ¹

Study	Model	Finding
EGF serum under-eye pilot (2015)	Humans, n=18 volunteers, open-label, no control	Twice-daily EGF serum reduced investigator-graded under-eye bag severity over the study period. ¹
FDA cosmetic versus drug guidance	Regulatory document	A topical product is a cosmetic or a drug depending on its claims; cosmetics are not pre-approved. ³

Safety

Reported tolerability in the pilot was good, with no serious adverse events. The theoretical concern with a growth factor is that it stimulates cell division indiscriminately, which is why dermatologists have raised questions about long-term use on sun-damaged skin or near skin cancers. No published evidence shows harm from cosmetic use, and no published evidence rules it out; the studies are too small and too short. ¹²

Questions for your clinician

Is there a controlled trial of oligopeptide-1 alone?
Is a growth-factor product sensible with sun-damaged skin?
Which ingredients have stronger evidence for my goal?

Questions people ask

Is oligopeptide-1 the same as EGF?

Yes. Oligopeptide-1 is the cosmetic ingredient name for epidermal growth factor. Prefixes such as sh- or rh- indicate it was made by recombinant methods and not extracted from tissue. ¹

Can a growth factor cause skin cancer?

No published study shows that cosmetic EGF does. The concern is theoretical: EGF receptor signaling is overactive in some cancers, so stimulating it on sun-damaged skin is a question worth asking. The small, short cosmetic studies cannot answer it. ¹²

Does it penetrate the skin?

EGF is a large protein, and intact skin blocks most molecules of that size. Products often pair it with penetration enhancers or recommend use after microneedling, which changes the safety picture as well. Direct measurements of how much reaches living skin layers from a cosmetic serum are lacking in these sources. ¹

Citations

Seidel 2015, J Drugs Dermatol: reduced appearance of under-eye bags with twice-daily application of EGF serum, a pilot study pubmed.ncbi.nlm.nih.gov
FDA: how cosmetics are not FDA-approved but are FDA-regulated fda.gov
FDA: is it a cosmetic, a drug, or both? fda.gov